Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05439421 · ClinicalTrials.gov registry record · NA
Consumer Perceptions of Waterpipe Tobacco Packaging and Digital Marketing Claims
A NA study of Waterpipe Tobacco Smoking, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 1,507
- Enrollment target
- 1
- Study location
NCT05439421: Completed NA study of Waterpipe Tobacco Smoking, sponsored by Wake Forest University Health Sciences.
NCT05439421 is a NA study of Waterpipe Tobacco Smoking that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 1,507 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05439421, a NA study of Waterpipe Tobacco Smoking, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,507 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the impact of marketing claims commonly found on waterpipe, also known as hookah, tobacco packages and in digital marketing on young adults' willingness to try hookah tobacco. Participants will complete two tasks, in random order. Participants will view six sample waterpipe tobacco packages, randomized at the package level to contain a prohibited or potentially-prohibited claim or not (Packaging Task). In the other task, they will view 10 digital marketing advertisements (i.e. Instagram posts or website pages) either with or without prohibited or potentially-prohibited claim, randomized at the advertisements level (Digital Marketing Task).
Primary Outcome
One item to assess the extent to which young adults are willing to try the waterpipe tobacco product: How likely would you be to try this specific product? Response scale: (1) Not at all likely to (4) Very likely
Conditions Studied
Interventions
- BEHAVIORAL Package/Advertisement With Claim
- BEHAVIORAL Package/Advertisement Without Claim
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,507 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2022-11-23 |
| Phase | NA |
What the finished NCT05439421 record still lists
NCT05439421 is an interventional study that assigns participants to a tested intervention. Its 1,507 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 1 condition, with Waterpipe Tobacco Smoking appearing as the primary indexed condition, and to 2 interventions - of which Package/Advertisement With Claim is the first listed.
NCT05439421 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05439421 about?
NCT05439421 is a clinical study titled "Consumer Perceptions of Waterpipe Tobacco Packaging and Digital Marketing Claims". The purpose of the study is to evaluate the impact of marketing claims commonly found on waterpipe, also known as hookah, tobacco packages and in digital marketing on young adults' willingness to try hookah tobacco. Participants will complete two tasks, in random order. Participants will view six sa...
What is the current status of trial NCT05439421?
This trial is currently completed. It is a NA study. The enrollment target is 1,507 participants. The study started on 2022-10-25. Estimated completion is 2022-11-23.
What conditions does trial NCT05439421 study?
This clinical trial studies the following conditions: Waterpipe Tobacco Smoking.
What interventions are being tested in trial NCT05439421?
The interventions under investigation include: Package/Advertisement With Claim (BEHAVIORAL), Package/Advertisement Without Claim (BEHAVIORAL).
Who is sponsoring clinical trial NCT05439421?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05439421 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05439421's enrollment target sits among peer trials
1,507 65th of 2000 higher than 1,936 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI